MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

ABSTRACT: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.

DISEASE(S): Angioimmunoblastic T-cell Lymphoma,Lymphoma,Cancer

PROVIDER: 2006457 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR